Unleashing the power of comparative oncology models in nanomedicine research

European Journal of Nanomedicine

Volumn 7, Issue 2, 2015, Pages 129-133

  Henry, Carolyn J ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

canine; model; oncology; preclinical; translational

Indexed keywords

DISEASES; MEDICAL NANOTECHNOLOGY; MODELS;

CANDIDATE DRUGS; CANINE; DRUG DEVELOPMENT; EFFICIENT PROCESS; FINANCIAL INVESTMENTS; PRECLINICAL; TRANSLATABILITY; TRANSLATIONAL;

ONCOLOGY;

NANOCARRIER;

ARTICLE; CANCER MODEL; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); EXPERIMENTAL NEOPLASM; HUMAN; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC);

EID: 84927926228     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2014-0046     Document Type: Article

References (29)

1. Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 2013;34:508-17.
2. Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 2012;18:3229-41.
3. Stirland DL, Nichols JW, Miura S, Bae YH. Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release 2013;172:1045-64.
4. 2012 US Pet ownership & demographics sourcebook. American Veterinary Medical Association.
5. American Cancer Society. Cancer facts and figures 2014. http://www.cancer.org/acs/groups/content/@research/documents/ webcontent/acspc-042151.pdf. Accessed on November 11, 2014.
6. Fleming JM, Creevy KE, Promislow DE. Mortality in North American Dogs from 1984 to 2004: An Investigation into Age-, Size-, and Breed-Related Causes of Death. J Vet Intern Med 2011;25:187-98.
7. National Cancer Institute Comparative Oncology Program. Available from https://ccrod.cancer.gov/confluence/pages/viewpage. action?pageId=46137977 Accessed on November 11, 2014.
8. Bronson RT. Variation in age at death of dogs of different sexes and breeds. Am J Vet Res 1982;43:2057-9.
9. Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer. Trends Mol Med 2011;17:380-8.
10. Cekanova M, Rathore K. Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des Devel Ther 2014;8:1911-22.
11. Henry CJ, Bryan JN. Not lost in translation: how study of diseases in our pets can benefit them and us. MO Med 2013;110:216-9.
12. Ranieri G, Gadaleta CD, Patruno R, Zizzo N, Daidone MG, Hansson MG, et al. A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol 2013;88:187-97.
13. Lindblad-Toh K, Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005;438:803-19.
14. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 2013;9:1-14.
15. Airley R. Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers? Future Med Chem 2012;4:1391-4.
16. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003;3:319-28.
17. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009;100:572-9.
18. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43.
19. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011;8:2101-41.
20. Xu Z, Gu W, Huang J, Sui H, Zhou Z, Yang Y, et al. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm 2005;288:361-8.
21. Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008;98:1608-13.
22. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/ Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9.
23. Hauck ML, LaRue SM, Petros WP, Poulson JM, Yu D, Spasojevic I, et al. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 2006;12:4004-10.
24. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med 2007;21:113-20.
25. Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, et al. Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer. Int J Nanomed 2014;9:5001-11.
26. Kamstock D, Guth A, Elmslie R, Kurzman I, Liggitt D, Coro L, et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 2006;13:306-17.
27. Gordon IK, Khanna C. Modeling opportunities in comparative oncology for drug development. ILAR J 2010;51:214-20.
28. Gordon I, Paoloni M, Mazcko C, Khanna C. The comparative oncology trials consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 2009;6:e1000161.
29. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 2009;4:e4972.